Group 1: Clinical Trials and Biotechnology - The phase I clinical trial for the type II herpes simplex virus mRNA vaccine developed by Zhuhai Lifanda Biotechnology Co., Ltd. and Changchun Baike Biotechnology Co., Ltd. has commenced, focusing on safety, tolerability, and immunogenicity among participants aged 18 to 55 [1] - Zhuhai Lifanda, established in June 2019, specializes in the development of mRNA drugs targeting infectious diseases, tumors, rare diseases, and other protein deficiency-related conditions [1] Group 2: Financial Services and Cross-Border Investment - The first EF account under the Macao dollar ODI business has been successfully processed by the Hengqin branch of China Construction Bank for Chip Tide (Zhuhai) Technology Co., Ltd., marking a significant milestone in cross-border financial services [2] - As of June 2025, the Hengqin branch has opened 103 EF accounts, becoming the first pilot bank to surpass 100 accounts, with a total fund transfer and foreign exchange volume exceeding 700 million yuan [2] Group 3: Real Estate and Housing Solutions - The "He Yu" rental platform, launched by Hengqin Shenhe Asset Management Co., Ltd., aims to address housing challenges for talent in the Hengqin Guangdong-Macao Deep Cooperation Zone by increasing the supply of high-quality housing [3] - The platform intends to enhance the rental process through technology, ensuring efficient matching between talent and housing resources, and aims to create a community ecosystem for residents [3] Group 4: Pharmaceutical and Traditional Medicine - Guangdong-Macao Pharmaceutical Co., Ltd., the only Chinese and EU GMP certified traditional Chinese medicine manufacturer in the Hengqin Guangdong-Macao Deep Cooperation Zone, has established a comprehensive production and quality management system [4] - As of July 2025, the company has provided production and registration agency services for over 20 types of Macao traditional Chinese medicine products, facilitating the integration of Macao's international platform with Hengqin's production capabilities [4] Group 5: Tourism and Cross-Border Travel - The Hengqin port has seen over 2.08 million inbound and outbound travelers during the summer period, representing a 27.6% increase compared to the same period last year, with 1.28 million from the mainland [5] - The implementation of convenient travel policies, such as "one visa multiple entries," has significantly boosted cross-border tourism products between Hengqin and Macao [6] Group 6: Industry Events and Support Initiatives - The 20th "China Chip" excellent product solicitation event is set to take place on October 29 in the Hengqin Guangdong-Macao Deep Cooperation Zone, with submissions open until August 30 [7] - The event aims to recognize outstanding chip products and enterprises, particularly in the automotive industry and RISC-V ecosystem promotion [7] - The cross-border e-commerce industry support application for the first half of 2025 has been officially launched, encouraging service providers to support e-commerce enterprises with various professional services [8]

Core Viewpoint - Anhui Huaheng Biotechnology Co., Ltd. is planning to issue overseas shares (H-shares) and list on the Hong Kong Stock Exchange, aiming to enhance its global development strategy and strengthen its market position [2] Group 1 - The company aims to leverage international capital market resources and mechanisms to optimize its capital structure [2] - The move is expected to broaden financing channels and improve corporate governance and overall strength [2] - This initiative is part of the company's strategy to enhance brand influence and core competitiveness [2]

Core Viewpoint - Lidman (300289.SZ) announced a significant asset restructuring plan, intending to acquire up to 70% of Beijing Xiansheng Xiangrui Biological Products Co., Ltd. through cash payment, which has led to a stock price surge of 19.93% to 7.04 yuan [1][2]. Group 1: Transaction Details - The transaction is expected to constitute a major asset restructuring as per the regulations, and it will not involve issuing new shares or result in a change of control [2][3]. - The funding for the acquisition will come from the company's own funds and bank merger loans [2][3]. - The framework agreement for the acquisition was signed on July 30, 2025, and the company did not hold any shares in the target company prior to this transaction [1][2]. Group 2: Financial Performance - In 2024, the company reported a revenue of 370.23 million yuan, a decrease of 19.79% compared to 2023 [3][4]. - The net profit attributable to shareholders was -75.10 million yuan, a decline of 589.66% from the previous year [3][4]. - The net cash flow from operating activities was 62.41 million yuan, down 52.29% year-on-year [3][4]. Group 3: Recent Quarterly Performance - For Q1 2025, the company reported a revenue of 78.91 million yuan, a decrease of 16.61% year-on-year [4]. - The net profit attributable to shareholders was -1.25 million yuan, an improvement of 53.73% compared to the same period last year [4]. - The net cash flow from operating activities for Q1 2025 was 10.69 million yuan, an increase of 25.64% year-on-year [4].

中国经济网北京7月31日讯华恒生物（688639.SH）昨晚发布关于筹划公司在香港联合交易所有限公司 上市的提示性公告。 华恒生物为深入推进公司全球化发展战略，提升品牌影响力与核心竞争力，巩固行业领先地位，充分借 助国际资本市场的资源与机制优势，优化资本结构，拓宽多元融资渠道，全面提升公司治理水平和综合 实力，正在筹划发行境外股份（H股）并在香港联合交易所有限公司（以下简称"香港联交所"）上市事 宜（以下简称"本次H股上市"）。公司正与相关中介机构就本次H股上市的具体推进工作进行商讨，相 关细节尚未确定，本次H股上市不会导致公司控股股东和实际控制人发生变化。 华恒生物于2021年4月22日在上交所科创板上市，保荐机构为兴业证券股份有限公司，保荐代表人为黄 超、饶毅杰。华恒生物公开发行募集资金总额为62532.00万元，募集资金净额为55925.88万元。华恒生 物于2021年4月16日披露的招股书显示，公司募集资金5.71亿元，分别用于交替年产2.5万吨丙氨酸、缬 氨酸项目、发酵法丙氨酸5000吨/年技改扩产项目、补充流动资金。 根据中国证券监督管理委员会出具的《关于同意安徽华恒生物科技股份有限公司向特定对象 ...

中国经济网北京7月31日讯 市场早盘震荡分化，截至午间收盘，上证指数报3591.26点，跌幅 0.68%；深证成指报11152.77点，跌幅0.45%；创业板指报2377.84点，涨幅0.43%。 | 序号 | 板块 | 涨跌幅(%)▼ | 总成交量(万手) ▼ | 总成交额(亿元) ▼ | 净流入(亿元) ▼ | 上涨家数 | 下跌家数 | | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 化学制药 | 2.21 | 3736.11 | 563.27 | 21.08 | 112 | 39 | | 2 | 软件开发 | 2.15 | 2165.17 | 483.02 | 48.85 | 109 | 28 | | 3 | 生物制品 | 2.14 | 666.38 | 151.85 | 9.26 | 38 | 14 | | 4 | 通信设备 | 1.85 | 1503.36 | 581.04 | 35.32 | 67 | 18 | | 5 | 医疗服务 | 1.71 | 908.17 | 236.63 | 5.05 | 41 | 12 | | б | ...

北京商报讯（记者丁宁）7月31日，利德曼（300289）"一"字涨停。截至北京商报记者发稿，利德曼报 涨停价7.04元/股，涨幅为19.93%。 消息面上，利德曼发布公告称，公司正在筹划以支付现金方式收购北京先声祥瑞生物制品股份有限公司 （以下简称"先声祥瑞"）部分股东持有的先声祥瑞合计不超过70%的股份。文章来源：北京商报原标 题：拟购先声祥瑞不超70%股权，利德曼"一"字涨停 ...

Economic Policy and Regulation - Xi Jinping emphasized the need for sustained macro policy efforts and timely enhancements in the second half of the year to address economic challenges and risks, focusing on expanding domestic demand and deepening reforms [1] - The Financial Regulatory Bureau's head, Li Yunze, conducted research in Tibet to enhance financial support for high-quality development and major projects, aiming to optimize financial services and mitigate risks [1] Corporate News - Ningde Times reported a net profit of 30.512 billion yuan for the first half of the year, a year-on-year increase of 33.02%, with operating revenue of 178.886 billion yuan, up 7.27% [5] - Digital Certification announced a change in its controlling shareholder to Beijing Data Group, following a transfer of state-owned shares [6] - Vanke A received a loan of up to 869 million yuan from its largest shareholder, Shenzhen Metro Group, for debt repayment and other purposes [6] - Changjiang Power plans to invest approximately 26.6 billion yuan in the Gezhouba shipping capacity expansion project, with funding sourced from its own capital [7] - Yonghui Supermarket intends to raise no more than 3.992 billion yuan through a private placement for store upgrades and working capital [7] Industry Developments - The China Metal Materials Circulation Association called for the abandonment of "involution-style" competition in the steel circulation industry, advocating for healthy competition based on product quality and service value [3] - Changying Precision announced that it has begun mass production of precision components for humanoid robots and has established partnerships with leading brands in the sector [8][9] - Longfly Fiber reported that its hollow-core fiber business has not yet significantly impacted its financial data, with future developments remaining uncertain [13]

消息面上，利德曼发布公告称，公司正在筹划以支付现金方式收购北京先声祥瑞生物制品股份有限公司 （以下简称"先声祥瑞"）部分股东持有的先声祥瑞合计不超过70%的股份。 北京商报讯（记者 丁宁）7月31日，利德曼（300289）"一"字涨停。截至北京商报记者发稿，利德曼报 涨停价7.04元/股，涨幅为19.93%。 ...

截至9时25分，利德曼涨停，涨幅19.93%，最新价7.04元，成交额0.36亿元，封单金额4.18亿元。公司7 月30日晚公告，拟以现金收购北京先声祥瑞生物制品股份有限公司不超过70%股份，交易预计构成重大 资产重组。目标公司主营结核诊断试剂及疫苗产品，2025年一季度利德曼营收7891万元，净利润亏损 125万元。 风险提示：收购事项尚处筹划阶段，存在审批未通过风险，二级市场波动需谨慎。 ...

Group 1 - The stock price of Baipusais experienced volatility on July 30, opening at 57.01 yuan, dropping to a low of 54.72 yuan, and closing at 55.41 yuan, a decrease of 2.21% from the previous trading day [1] - During the trading session, there was a rapid rebound, with the stock price increasing over 2% within 5 minutes at 9:37 AM, reaching 57.27 yuan [1] - On July 30, the net outflow of main funds was 1.583 million yuan, accounting for 0.02% of the circulating market value, with a trading volume of 41,500 lots and a transaction amount of 233 million yuan [1] Group 2 - Baipusais is a company focused on the biopharmaceutical sector, primarily engaged in the research, development, production, and sales of recombinant proteins and other biological products [1] - The company's products are mainly applied in drug research and development, as well as vaccine production [1]